Mikhail Blagosklonny is a professor of oncology at the Rosewell Park Cancer Institute as well as a respected researcher in the field of biogerontology on msubmit.net. Blagosklonny earned both his M.D. and his PhD at First Pavlov State Medical University of St. Petersburg. In 2002 he became an associate professor of medicine at New York Medical college. After leaving that job he served as a senior scientist on bioxbio.com at Ordway Research Institute until 2009. Since then, he has served in his current position at Rosewell Park Cancer Institute.
Blagosklonny has spent much of his time researching the potential role of TOR signaling in both aging and cancer and can be seen in Oncotarget. He is considered one of the most vocal advocates for use of certain cancer drugs in preventing aging and extending human life. This treatment has been shown to increase the lifespan of lab mice by as much as 60%, however human research is still in its infancy on ncbi.nlm.nih.gov.
Mikhail Blagosklonny also plays a prominent role in scientific publications, Oncotarget. Currently, he is serving as editor-in-chief for three different publications like Oncotarget. The first is Aging, a peer-reviewed, open-access medical journal that comes out once a month. Second is Cell Cycle, a bi-weekly journal which coveres topics related to call biology. Lastly is weekly journal called Oncotarget, which covers all areas of oncology. He is also a member of the editorial board for a publication call Cell Death and Differentiation, as well as an associate editor for Cancer Biology and Therapy.